Vaxcyte, Inc.
General ticker "PCVX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.7B (TTM average)
Vaxcyte, Inc. follows the US Stock Market performance with the rate: 45.6%.
Estimated limits based on current volatility of 3.0%: low 47.13$, high 50.05$
Factors to consider:
- Total employees count: 414 (+63.0%) as of 2024
- Top business risk factors: Product commercialization failure, Operational and conduct risks, Manufacturing risks, Public perception, Cybersecurity threats
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [27.37$, 60.97$]
- 2026-12-31 to 2027-12-31 estimated range: [21.31$, 49.75$]
Financial Metrics affecting the PCVX estimates:
- Negative: with PPE of -8.2 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 6.96 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PCVX quotes
Long-term PCVX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $468.04MM | $569.55MM | $923.67MM |
| Operating Income | $-468.04MM | $-569.55MM | $-923.67MM |
| Non-Operating Income | $65.78MM | $105.62MM | $157.05MM |
| R&D Expense | $332.34MM | $476.64MM | $794.31MM |
| Income(Loss) | $-402.27MM | $-463.93MM | $-766.63MM |
| Net Income(Loss)* | $-402.27MM | $-463.93MM | $-766.63MM |
| Stockholders Equity | $1,240.47MM | $3,305.82MM | $2,685.51MM |
| Assets | $1,407.92MM | $3,511.32MM | $3,002.72MM |
| Operating Cash Flow | $-296.79MM | $-452.63MM | $-655.58MM |
| Capital expenditure | $67.88MM | $22.43MM | $13.71MM |
| Investing Cash Flow | $-773.31MM | $-2,005.67MM | $437.35MM |
| Financing Cash Flow | $639.81MM | $2,448.51MM | $2.01MM |
| Earnings Per Share** | $-4.14 | $-3.80 | $-5.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.